Ascent Wealth Partners LLC Purchases 8,516 Shares of Pfizer Inc. (NYSE:PFE)

Ascent Wealth Partners LLC grew its position in Pfizer Inc. (NYSE:PFE) by 12.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 75,259 shares of the biopharmaceutical company’s stock after acquiring an additional 8,516 shares during the period. Ascent Wealth Partners LLC’s holdings in Pfizer were worth $2,106,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Olistico Wealth LLC bought a new position in shares of Pfizer in the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer in the second quarter valued at approximately $29,000. Creekmur Asset Management LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $32,000. Trivant Custom Portfolio Group LLC raised its stake in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. bought a new position in shares of Pfizer in the second quarter valued at approximately $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 1.0 %

Shares of PFE traded up $0.29 during trading hours on Friday, reaching $29.01. The stock had a trading volume of 37,137,599 shares, compared to its average volume of 38,496,418. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $36.29. The firm has a 50-day moving average of $28.99 and a 200 day moving average of $28.01. The company has a market cap of $164.39 billion, a P/E ratio of -483.50, a P/E/G ratio of 0.98 and a beta of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter in the prior year, the company earned $0.67 EPS. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.68 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.79%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s dividend payout ratio is currently -2,800.00%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research reports. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Barclays raised their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. UBS Group raised their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Finally, StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.